Humacyte (NASDAQ:HUMA) Shares Down 6.2% – Time to Sell?

Shares of Humacyte, Inc. (NASDAQ:HUMA) traded down 6.2% on Monday . The stock traded as low as $5.31 and last traded at $5.42. 867,045 shares were traded during trading, a decline of 63% from the average session volume of 2,357,155 shares. The stock had previously closed at $5.78.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a report on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Price Performance

The company has a 50 day moving average of $5.45 and a 200 day moving average of $6.18. The company has a quick ratio of 5.41, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, equities analysts forecast that Humacyte, Inc. will post -1.18 earnings per share for the current year.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares in the company, valued at $28,896,373.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of Humacyte stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,084,153 shares of company stock worth $6,869,996. 11.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Humacyte

Several large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Humacyte by 28.5% during the 3rd quarter. FMR LLC now owns 94,387 shares of the company’s stock worth $513,000 after purchasing an additional 20,930 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Humacyte by 30.5% in the third quarter. The Manufacturers Life Insurance Company now owns 45,575 shares of the company’s stock worth $248,000 after purchasing an additional 10,656 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Humacyte by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after buying an additional 66,946 shares in the last quarter. Intech Investment Management LLC bought a new stake in Humacyte in the 3rd quarter valued at $232,000. Finally, Thrivent Financial for Lutherans bought a new stake in Humacyte in the third quarter valued at about $712,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.